Detailed information for compound 265370
Basic information
Technical information
- Name: Unnamed compound
- MW: 573.368 | Formula: C26H28BN9O6
-
H donors: 7
H acceptors: 10
LogP: -0.25
Rotable bonds: 13
Rule of 5 violations (Lipinski): 3 - SMILES: O=C(Nc1cccc(c1)B(O)O)CCC(C(=O)O)NC(=O)c1ccc(cc1)N(Cc1cnc2c(n1)c(N)nc(n2)N)C
- InChi: 1S/C26H28BN9O6/c1-36(13-17-12-30-23-21(32-17)22(28)34-26(29)35-23)18-7-5-14(6-8-18)24(38)33-19(25(39)40)9-10-20(37)31-16-4-2-3-15(11-16)27(41)42/h2-8,11-12,19,41-42H,9-10,13H2,1H3,(H,31,37)(H,33,38)(H,39,40)(H4,28,29,30,34,35)
- InChiKey: ONOSXQXDILCQLT-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | dihydrofolate reductase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | dihydrofolate reductase | 187 aa | 202 aa | 29.7 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0208 | 0.5 | 0.5 |
| Echinococcus multilocularis | dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Chlamydia trachomatis | dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Schistosoma mansoni | dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0208 | 0.5 | 0.5 |
| Brugia malayi | Dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Loa Loa (eye worm) | dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Echinococcus granulosus | dihydrofolate reductase | 0.0208 | 0.5 | 0.5 |
| Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0208 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (functional) | = 0.7 nM | Compound was evaluated for the growth inhibition of L1210 cells. | ChEMBL. | 1995880 |
| IC50 (functional) | = 0.7 nM | Compound was evaluated for the growth inhibition of L1210 cells. | ChEMBL. | 1995880 |
| IC50 (binding) | = 30 nM | Inhibition of dihydrofolate reductase (DHFR) from human cells (WI-L2/M4). | ChEMBL. | 1995880 |
| IC50 (binding) | = 30 nM | Inhibition of dihydrofolate reductase (DHFR) from human cells (WI-L2/M4). | ChEMBL. | 1995880 |
| Survival median (functional) | = 11 day | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival median (functional) | = 11 day | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival median (functional) | = 12 day | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival median (functional) | = 12 day | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival median (functional) | = 14 day | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival median (functional) | = 14 day | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as Survival median in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 9 day | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 9 day | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 11 day | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 11 day | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 12 day | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| Survival range (functional) | = 12 day | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as Survival range in days | ChEMBL. | 1995880 |
| T/C (functional) | = 4 % | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 4 % | In vivo activity against L1210 leukemia cells in mice at a dose of 16 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 5 % | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 5 % | In vivo activity against L1210 leukemia cells in mice at a dose of 32 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 8 % | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 8 % | In vivo activity against L1210 leukemia cells in mice at a dose of 8 mg/kg and expressed as percent weight change after 7 days | ChEMBL. | 1995880 |
| T/C (functional) | = 138 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 8 mg/kg | ChEMBL. | 1995880 |
| T/C (functional) | = 138 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 8 mg/kg | ChEMBL. | 1995880 |
| T/C (functional) | = 150 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 16 mg/kg | ChEMBL. | 1995880 |
| T/C (functional) | = 150 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 16 mg/kg | ChEMBL. | 1995880 |
| T/C (functional) | = 175 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 32 mg/kg | ChEMBL. | 1995880 |
| T/C (functional) | = 175 % | Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 32 mg/kg | ChEMBL. | 1995880 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Mus musculus | ChEMBL23 | 1995880 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL157117
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.